Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Review, H2 2016', provides in depth analysis on Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted pipeline therapeutics. The report provides comprehensive information on the Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - The report reviews Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics and enlists all their major and minor projects - The report assesses Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Overview 7 Therapeutics Development 8 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Stage of Development 8 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Therapy Area 9 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Indication 10 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Companies 13 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Companies Involved in Therapeutics Development 19 AstraZeneca Plc 19 C&C Research Laboratories 20 CymaBay Therapeutics Inc 21 Jiangsu Hengrui Medicine Co Ltd 22 Nippon Chemiphar Co Ltd 23 Wellstat Therapeutics Corp 24 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Drug Profiles 25 (allopurinol + lesinurad) - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 arhalofenate - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 JPH-367 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 NC-2700 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 RLBN-1001 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 SHR-4640 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 URC-102 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 verinurad - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 WT-2107 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Dormant Projects 39 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Discontinued Products 40 Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Featured News & Press Releases 41 Mar 28, 2016: CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology 41 Jan 20, 2016: CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate 42 Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 43 Aug 06, 2015: CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents 44 Jun 12, 2015: CymaBay Therapeutics Presents Poster at EULAR 2015 44 Mar 23, 2015: CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City 45 Mar 03, 2015: Vince & Associates Clinical Research Completes CymaBay Therapeutics Clinical Trial of Arhalofenate in Combination with Febuxostat 46 Feb 24, 2015: CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares 46 Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 47 Sep 29, 2014: CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout 49 Mar 26, 2014: CymaBay Initiates Arhalofenate Phase 2b Gout Study 49 Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 49 Nov 07, 2011: Ardea Biosciences Presents Initial Clinical Results For RDEA3170 At 2011 ACR/ARHP Annual Scientific Meeting 50 Nov 01, 2011: Metabolex To Present Data On Arhalofenate At 2011 ACR/AHP Annual Scientific Meeting 51 May 19, 2011: Metabolex Initiates Phase II Trial Of Arhalofenate For Treatment Of Gout 51 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by AstraZeneca Plc, H2 2016 19 Pipeline by C&C Research Laboratories, H2 2016 20 Pipeline by CymaBay Therapeutics Inc, H2 2016 21 Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 22 Pipeline by Nippon Chemiphar Co Ltd, H2 2016 23 Pipeline by Wellstat Therapeutics Corp, H2 2016 24 Dormant Projects, H2 2016 39 Discontinued Products, H2 2016 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
